Sumitomo Mitsui Trust Holdings Inc. increased its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 785,050 shares of the pharmaceutical company’s stock after buying an additional 8,064 shares during the quarter. Sumitomo Mitsui Trust Holdings Inc. owned 0.31% of Vertex Pharmaceuticals worth $119,359,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds have also made changes to their positions in VRTX. Northwestern Mutual Wealth Management Co. grew its stake in Vertex Pharmaceuticals by 15.4% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 988 shares of the pharmaceutical company’s stock worth $127,000 after buying an additional 132 shares during the last quarter. FNY Partners Fund LP lifted its position in Vertex Pharmaceuticals by 900.0% during the 2nd quarter. FNY Partners Fund LP now owns 1,000 shares of the pharmaceutical company’s stock worth $128,000 after acquiring an additional 900 shares during the period. Smithfield Trust Co. acquired a new stake in Vertex Pharmaceuticals during the 3rd quarter worth about $135,000. Dupont Capital Management Corp acquired a new stake in Vertex Pharmaceuticals during the 2nd quarter worth about $186,000. Finally, State of Alaska Department of Revenue acquired a new stake in Vertex Pharmaceuticals during the 2nd quarter worth about $197,000. Hedge funds and other institutional investors own 92.79% of the company’s stock.
In other Vertex Pharmaceuticals news, EVP David Altshuler sold 1,796 shares of the company’s stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $160.00, for a total transaction of $287,360.00. Following the transaction, the executive vice president now directly owns 107,807 shares in the company, valued at $17,249,120. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Ian F. Smith sold 2,125 shares of the company’s stock in a transaction on Monday, October 16th. The stock was sold at an average price of $155.61, for a total value of $330,671.25. Following the transaction, the chief operating officer now owns 118,013 shares in the company, valued at $18,364,002.93. The disclosure for this sale can be found here. Insiders sold 220,094 shares of company stock worth $32,074,719 over the last quarter. 1.80% of the stock is currently owned by insiders.
Vertex Pharmaceuticals Incorporated (NASDAQ VRTX) traded up $0.84 on Thursday, reaching $148.66. The company had a trading volume of 1,086,600 shares, compared to its average volume of 1,818,027. Vertex Pharmaceuticals Incorporated has a 12-month low of $71.46 and a 12-month high of $167.85. The firm has a market capitalization of $37,600.00, a PE ratio of 246.37, a PEG ratio of 3.76 and a beta of 1.63. The company has a quick ratio of 3.14, a current ratio of 3.28 and a debt-to-equity ratio of 0.01.
Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Wednesday, October 25th. The pharmaceutical company reported $0.53 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.49. Vertex Pharmaceuticals had a return on equity of 9.23% and a net margin of 8.53%. The firm had revenue of $578.20 million for the quarter, compared to analysts’ expectations of $522.07 million. During the same period in the prior year, the firm posted $0.16 earnings per share. The firm’s quarterly revenue was up 39.7% on a year-over-year basis. equities analysts predict that Vertex Pharmaceuticals Incorporated will post 0.72 earnings per share for the current year.
A number of analysts have commented on VRTX shares. Cowen and Company reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, August 1st. Zacks Investment Research cut Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 24th. Credit Suisse Group lifted their price target on Vertex Pharmaceuticals from $125.00 to $195.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 19th. DA Davidson started coverage on Vertex Pharmaceuticals in a research report on Friday, September 29th. They set a “buy” rating and a $200.00 price target for the company. Finally, Jefferies Group LLC reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, August 22nd. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-three have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $173.15.
WARNING: “Vertex Pharmaceuticals Incorporated (VRTX) Shares Bought by Sumitomo Mitsui Trust Holdings Inc.” was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://ledgergazette.com/2017/11/16/vertex-pharmaceuticals-incorporated-vrtx-shares-bought-by-sumitomo-mitsui-trust-holdings-inc.html.
Vertex Pharmaceuticals Profile
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).
Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.